Corvus Pharmaceuticals, Inc.
CRVS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $8 | $8 | $7 | $6 |
| G&A Expenses | $2 | $2 | $2 | $2 |
| SG&A Expenses | $2 | $2 | $2 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $11 | $10 | $10 | $8 |
| Operating Income | -$11 | -$10 | -$10 | -$8 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $2 | $25 | -$4 |
| Pre-Tax Income | -$10 | -$8 | $15 | -$12 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$10 | -$8 | $15 | -$12 |
| % Margin | – | – | – | – |
| EPS | -0.12 | -0.1 | 0.21 | -0.18 |
| % Growth | -20% | -147.6% | 216.7% | – |
| EPS Diluted | -0.12 | -0.1 | -0.13 | -0.18 |
| Weighted Avg Shares Out | 83 | 78 | 72 | 68 |
| Weighted Avg Shares Out Dil | 83 | 78 | 75 | 68 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$10 | -$10 | -$10 | -$8 |
| % Margin | – | – | – | – |